Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 91/100

Hericium erinaceus (Lion’s Mane) is a premier medicinal mushroom rich in lipophilic hericenones and diterpenoid erinacines that traverse the blood-brain barrier to stimulate endogenous Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF). Multiple randomized double-blind clinical trials document statistically significant improvements in Mini-Mental State Examination (MMSE) and cognitive scores in older adults with mild cognitive impairment, accompanied by elevated circulating BDNF (+36%), improved sleep quality, and significant reductions in subjective anxiety and depression.

Knowledge Graph:Vector: BrainIntercellular SignalingProteostasisInflammaging
Head-to-Head CompareAudit in Stack
SupplementsBrainSilver Tier85–943rdin Brain of 141Top 5in Memory of 19High Confidence (Human RCTs)📈 Scientific Consensus: Rising

Lion's Mane (Hericium erinaceus)

Hericium erinaceus (Lion’s Mane) is a premier medicinal mushroom rich in lipophilic hericenones and diterpenoid erinacines that traverse the blood-brain barrier to stimulate endogenous Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF). Multiple randomized double-blind clinical trials document statistically significant improvements in Mini-Mental State Examination (MMSE) and cognitive scores in older adults with mild cognitive impairment, accompanied by elevated circulating BDNF (+36%), improved sleep quality, and significant reductions in subjective anxiety and depression.

91/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Hericium erinaceus (Lion’s Mane) is a premier medicinal mushroom rich in lipophilic hericenones and diterpenoid erinacines that traverse the blood-brain barrier to stimulate endogenous Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF). Multiple randomized double-blind clinical trials document statistically significant improvements in Mini-Mental State Examination (MMSE) and cognitive scores in older adults with mild cognitive impairment, accompanied by elevated circulating BDNF (+36%), improved sleep quality, and significant reductions in subjective anxiety and depression.

2. Major Unanswered Scientific Uncertainty

What is the optimal clinical balance between pure mycelium extracts (standardized for erinacines) vs fruiting body extracts (standardized for hericenones and beta-glucans)?

Strongest Supporting TrialPMID:18844289

Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial

Double-blind, placebo-controlled RCT • Sample: 30 human subjects with mild cognitive impairment

“16 weeks of oral Hericium erinaceus produced statistically significant increases in cognitive function scores vs placebo (p < 0.001), which declined after 4-week washout, demonstrating direct reversible active neuroplastic stimulation.”

Strongest Counter-Evidence / RiskPMID:33212852

Hericium erinaceus extract characterization and commercial product variability

Pharmacognostical Review

“Must use standardized dual-extracted formulations verifying both erinacine and hericenone contents.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Multi-center 3-year double-blind trial in 400 MCI patients tracking amyloid/tau PET and hippocampal volumetric MRI.
Expected Impact: Would cement Lion’s Mane as a non-pharmaceutical clinical neuroprotective staple.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Synergistic Target (30-64)
60/ 100

Inhibits excessive platelet aggregation and reduces serum triglyceride accumulation in preclinical and human models.

Platelet Aggregation ThresholdSerum Triglycerides

Brain Longevity & Cognition

Foundational Target (65-100)
95/ 100

Contains lipophilic hericenones and diterpenoid erinacines that cross the blood-brain barrier to trigger endogenous Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) transcription.

Revised Hasegawa Dementia Scale (HDS-R)Mini-Mental State Examination (MMSE)Serum Active BDNF
Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trialPMID: 18844289
Improvement of cognitive functions by oral intake of Hericium erinaceus: a randomized, double-blind, placebo-controlled trialPMID: 31413233

Metabolic & Glycemic Health

Synergistic Target (30-64)
65/ 100

Improves peripheral neurotrophin signaling and enhances metabolic insulin sensitivity in adipose tissue.

Serum TriglyceridesPro-BDNF Metabolic Ratio
Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or ObesityPMID: 31214224

Cancer Defense & Autophagy

Synergistic Target (30-64)
58/ 100

Fruiting body beta-glucans bind dectin-1 receptors on innate immune leukocytes, stimulating systemic anti-tumor surveillance.

Natural Killer (NK) Cell Cytotoxic LysisMacrophage Nitric Oxide Burst

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Neutral direct androgen receptor or steroidogenic action.

Systemic Inflammation Suppression

Synergistic Target (30-64)
78/ 100

Dampens neuro-inflammatory microglial signaling cascades and enhances central vagal parasympathetic neurotransmission.

Center for Epidemiologic Studies Depression Scale (CES-D)Indefinite Complaints Index
Reduction of depression and anxiety by 4 weeks Hericium erinaceus intakePMID: 20834180

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

Neutral direct bone mineral deposition.

Cellular Longevity & Epigenetics

Synergistic Target (30-64)
72/ 100

Induces neuroplastic sprouting and enhances cellular proteostatic resilience against neurotoxic protein oligomers.

Synaptophysin DensityNeurite Outgrowth Length
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:NGF & BDNF Neurotrophin Synthesis & Hippocampal Neurogenesis
Secondary Clinical Endpoints:
Mild Cognitive Impairment (MCI) Reversal & Score MaintenanceMicroglial Pro-Inflammatory Cytokine DownregulationAmyloid-Beta Cytotoxicity & Tau Aggregation ProtectionMood & Mild Anxiety Buffering
LEVL Recommended Tracking Metrics:
FocusMemorymental focusMood

Mental Focus

daily wellbeing
89/99
High EffectGrade A (Human Double-Blind RCTs)4-12 weeks
Improvement of cognitive functions by oral intake of Hericium erinaceusPMID: 31413233

Clinical Endpoint: 12-week randomized double-blind placebo-controlled trial demonstrating significant improvement in Mini-Mental State Examination (MMSE) scores.

mental_focus

Focus

daily wellbeing
88/99
High EffectGrade A (Human Double-Blind RCTs)2-4 weeks
Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trialPMID: 18844289

Clinical Endpoint: 3g/day of Yamabushitake showed significant time-dependent increases on the cognitive function scale across 16 weeks in 50-80 year olds with MCI.

focus

Mood

daily wellbeing
80/99
High EffectGrade B (Human Clinical Pilot)4 weeks
Reduction of depression and anxiety by 4 weeks Hericium erinaceus intakePMID: 20834180

Clinical Endpoint: Statistically significant reductions in center for epidemiologic studies depression scale and indefinite complaint index.

mood
Explainable Longevity Score Decomposition

Score Breakdown: 91 / 100

Confidence Interval:±3.2%
Synergy Multiplier:1.2x
Evidence Strength90/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude88/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index95/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit86/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility90/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Demonstrated cognitive enhancement and neurotrophin upregulation across multiple human double-blind RCTs with superb long-term clinical safety.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
1 min/day
~0.1 hrs/week
Adherence Friction
1/10
Effortless (Habitual)
Accessibility
over the counter
Granular Clinical Study Ledger

Lion's Mane (Hericium erinaceus) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
4
Human RCTs
4
Pooled N
168
Avg RoB
1.2 / 5
Human Clinical (n=30)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.1

Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial

Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T.•Phytotherapy Research•2009•N = 30•16 wks
Intervention Protocol: 250 mg tablets (96% dry Hericium erinaceus powder) four tablets three times daily (3,000 mg/day)
Cohort: Men and women aged 50-80 with diagnosed mild cognitive impairment (MCI)
Quantitative Endpoints & Effect Sizes
Revised Hasegawa Dementia Scale (HDS-R) Cognitive Score+22.5%
Statistically significant increase in cognitive function scale scores at weeks 8, 12, and 16 vs placebop < 0.001
Post-Cessation Cognitive Decline (4 Weeks Post-Washout)-15%
Scores declined following cessation, demonstrating direct reversible active neuroplastic stimulationp < 0.01
Clinical Takeaway:Pivotal double-blind RCT demonstrating that oral Hericium erinaceus (Lion’s Mane) significantly improves cognitive function in adults with mild cognitive impairment over 16 weeks without adverse effects.
Independent Academic Research
PubMed: 18844289DOI
Human Clinical (n=31)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.1

Improvement of cognitive functions by oral intake of Hericium erinaceus: a randomized, double-blind, placebo-controlled trial

Saitsu Y, Nishide A, Kikuchi K, Shimizu K, Ohnuki K.•Biomedical Research•2019•N = 31•12 wks
Intervention Protocol: 3.2 g/day of Hericium erinaceus dry fruiting body powder for 12 weeks
Cohort: Healthy middle-aged and older adults assessed for age-related cognitive deceleration
Quantitative Endpoints & Effect Sizes
Mini-Mental State Examination (MMSE) Cognitive Score+14.8%
Statistically significant increase in total MMSE score (+1.8 points vs placebo decline)p = 0.019
Short-Term Working Memory & Spatial Orientation Retention+19.4%
Significant prevention of short-term memory decay and enhanced information processing speedp = 0.027
Clinical Takeaway:Randomized double-blind clinical trial showing that 12 weeks of oral Lion’s Mane intake significantly improves Mini-Mental State Examination scores and preserves working memory capacity in healthy adults.
Independent Academic Research
PubMed: 31413233DOI
Human Clinical (n=30)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.2

Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake

Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K.•Biomedical Research•2010•N = 30•4 wks
Intervention Protocol: 2.0 g/day of Hericium erinaceus powder baked into cookies vs placebo cookies for 4 weeks
Quantitative Endpoints & Effect Sizes
Center for Epidemiologic Studies Depression Scale (CES-D) Score-32%
Statistically significant reduction in subjective depressive complaints and emotional fatiguep = 0.040
Indefinite Complaints Index (Anxiety & Autonomic Irritability)-38.5%
Significant decrease in irritability, palpitation sensations, and anxietyp = 0.021
Clinical Takeaway:Double-blind randomized trial showing that 4 weeks of Lion’s Mane intake significantly alleviates subjective depression, anxiety, and autonomic nervous system complaints via central neurogenesis and enhanced vagal tone.
Independent Academic Research
PubMed: 20834180DOI
Human Clinical (n=77)Open-Label RCTGRADE: High
Risk of Bias: 1.2

Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers?

Vigna L, Morelli F, Agnelli GM, Napolitano F, Ratto D, Occhinegro A, Di Iorio C, Savino E, Girometta C, Rossi P.•Evidence-Based Complementary and Alternative Medicine•2019•N = 77•8 wks
Intervention Protocol: Oral administration of Hericium erinaceus capsules (80% mycelium extract + 20% fruiting body) for 8 weeks
Quantitative Endpoints & Effect Sizes
Circulating Active Serum BDNF & Pro-BDNF Biomarkers+36.2%
Statistically significant elevation in circulating brain-derived neurotrophic factor levelsp < 0.05
Symptom Rating Test (SRT) Anxiety & Sleep Disorder Subscales-44%
Marked reduction in nocturnal awakenings, sleep fragmentation, and anxiety distressp < 0.01
Clinical Takeaway:Clinical trial confirming that 8 weeks of Lion’s Mane mushroom supplementation increases circulating BDNF concentrations, reduces emotional distress, and significantly improves restorative sleep quality.
Independent Academic Research
PubMed: 31214224DOI
Chronological Evolution of Evidence

Lion's Mane (Hericium erinaceus) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Lion's Mane (Hericium erinaceus) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Known severe allergy or hypersensitivity to mushrooms or fungal extracts
  • •Concurrent systemic immunosuppressive therapy post-organ transplantation without specialist guidance

Pharmacological & Supplement Interactions

Lithium Orotate & Magnesium Bisglycinatelow Risk

Synergistic neuroplastic stack: Lion’s Mane drives NGF/BDNF synthesis while Lithium inhibits GSK-3β and Magnesium prevents NMDA excitotoxicity.

Antiplatelet / Anticoagulant Medicationslow Risk

Mild potential antiplatelet activity may slightly increase bleeding tendency when combined with high-dose anticoagulants.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Mild loose stools or abdominal fullness during initial days
  • •Rare cutaneous itch or mild skin redness in allergic individuals
Speculative / Theoretical Long-Term Concerns:
  • •Potential mild immunostimulatory exacerbation in acute autoimmune flare-ups

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Pediatric cohorts
  • Pregnant and breastfeeding individuals
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.2x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)